The U.S. Supreme Court today heard arguments over whether big pharmaceutical companies can pay generic drug manufacturers to delay their entry into the marketplace. In FTC v. Actavis, the court will rule if payments made to preserve a name-brand prescription drug’s grip on the market count as collusion that violates federal antitrust laws, as the Federal Trade Commission is arguing. Opponents of the “pay-to-delay” system claim that the name-brand companies are essentially bribing their cheaper competitors to stay away, in …
Read More Leave a Comment





